Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 6/20 | 0.70 |
| ▸ | GNAO1 | P09471 | 6/20 | 0.70 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.48 |
| ▸ | EBP | Q15125 | 1/20 | 0.48 |
| ▸ | GUSB | P08236 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1043043 | 1.00 | GNAI3 (0.70) | GNAI3GNAO1GNAI1KDM4EGAA | |
| SCHEMBL35895 | 1.00 | — | — | |
| SCHEMBL1219079 | 0.97 | GNAI3 (0.74) | GNAI3GNAO1GNAI1KDM4EGAA | |
| SCHEMBL18092757 | 0.97 | GNAI3 (0.74) | GNAI3GNAO1GNAI1KDM4EGAA | |
| SCHEMBL7022103 | 0.97 | GNAI3 (0.74) | GNAI3GNAO1GNAI1KDM4EGAA | |
| SCHEMBL7991671 | 0.97 | GNAI3 (0.74) | GNAI3GNAO1GNAI1KDM4EGAA | |
| SCHEMBL6566402 | 0.97 | GNAI3 (0.74) | GNAI3GNAO1GNAI1KDM4EGAA | |
| SCHEMBL1043024 | 0.97 | GNAI3 (0.74) | GNAI3GNAO1GNAI1KDM4EGAA | |
| SCHEMBL1043420 | 0.97 | GNAI3 (0.74) | GNAI3GNAO1GNAI1KDM4EGAA | |
| SCHEMBL11571907 | 0.97 | GNAI3 (0.74) | GNAI3GNAO1GNAI1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 229 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1771162-B1 | CAPSAICIN INHIBITORS FOR THE TREATMENT OF OBESITY-RELATED DISORDERS | XENIA PHARMA (DK) | 2013-06-05 | — | — | EP | claimed |
| US-20120004242-A1 | Oligomer-Diarylpiperazine Conjugates | NEKTAR THERAPEUTICS (US) | 2012-01-05 | — | — | US | claimed |
| US-20110224147-A1 | METHODS AND COMPOSITIONS | Relevare Aust. Pyt. Ltd. (AU) | 2011-09-15 | — | — | US | claimed |
| JP-2011510078-A | — | — | 2011-03-31 | — | — | JP | claimed |
| US-20100316678-A1 | COMBINATION METHODS AND COMPOSITIONS FOR TREATMENT OF NEUROPATHIC PAIN | CNSBIO PTY LTD. (AU) | 2010-12-16 | — | — | US | claimed |
| EP-2249872-A1 | OLIGOMER-DIARYLPIPERAZINE CONJUGATES | Nektar Therapeutics (US) | 2010-11-17 | — | — | EP | claimed |
| JP-4574167-B2 | — | — | 2010-11-04 | — | — | JP | claimed |
| EP-2175886-A1 | COMBINATION METHODS AND COMPOSITIONS FOR TREATMENT OF NEUROPATHIC PAIN | CNSBio Pty Ltd (AU) | 2010-04-21 | — | — | EP | claimed |
| WO-2010012043-A1 | METHODS AND COMPOSITIONS | CNSBIO PTY LTD (AU) | 2010-02-04 | — | — | WO | claimed |
| WO-2009094209-A1 | OLIGOMER-DIARYLPIPERAZINE CONJUGATES | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-07-30 | — | — | WO | claimed |
| US-6177450-B1 | MIXTURE OF PERHYDROISOINDENE COMPOUND AND BENEZAMIDE COMPOUND | AVENTIS PHARMA S.A. | 2001-01-23 | — | — | US | claimed |
| EP-0786482-B1 | Liquid system for the anionic lactam polymerisation | INVENTA AG (CH) | 2000-08-16 | — | — | EP | claimed |
| WO-1999007413-A1 | SUBSTANCE P INHIBITORS IN COMBINATION WITH NMDA-BLOCKERS FOR TREATING PAIN | ALGOS PHARMACEUTICAL CORPORATION (US) | 1999-02-18 | — | — | WO | claimed |
| EP-0680323-B1 | SYNERGISING ASSOCIATION HAVING AN ANTAGONIST EFFECT ON NK1 AND NK2 RECEPTORS | RHONE POULENC RORER SA (FR) | 1997-04-02 | — | — | EP | claimed |
| EP-0680323-A1 | SYNERGISING ASSOCIATION HAVING AN ANTAGONIST EFFECT ON NK1 AND NK2 RECEPTORS. | RHONE POULENC RORER SA (FR) | 1995-11-08 | — | — | EP | claimed |
| WO-1994016697-A1 | SYNERGISING ASSOCIATION HAVING AN ANTAGONIST EFFECT ON NK1 AND NK2 RECEPTORS | RHONE-POULENC RORER S.A. (FR) | 1994-08-04 | — | — | WO | claimed |
| US-4561451-A | 1,4-Diacylpiperazine flavored smoking compositions | PHILIP MORRIS INCORPORATED (US) | 1985-12-31 | — | — | US | claimed |
| EP-0116640-A4 | 1,4-DIACYLPIPERAZINE FLAVORED SMOKING COMPOSITIONS. | PHILIP MORRIS INC (US) | 1984-12-11 | — | — | EP | claimed |
| EP-0116640-A1 | 1,4-DIACYLPIPERAZINE FLAVORED SMOKING COMPOSITIONS | PHILIP MORRIS INCORPORATED (US) | 1984-08-29 | — | — | EP | claimed |
| WO-1984000672-A1 | 1,4-DIACYLPIPERAZINE FLAVORED SMOKING COMPOSITIONS | PHILIP MORRIS INC (US) | 1984-03-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224147-A1 | METHODS AND COMPOSITIONS | OPRK1, OPRL1, OPRM1 | GNAI3 2139/4885GNAO1 575/4885GNAI1 1361/4885 |
| US-20120004242-A1 | Oligomer-Diarylpiperazine Conjugates | BIRC5, MTX2, IAPP | GNAI3 2186/4885GNAO1 2727/4885GNAI1 2731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.